- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: Cedazuridine.
Displaying page 1 of 1.
EudraCT Number: 2020-004772-18 | Sponsor Protocol Number: ASTX727-07 | Start Date*: 2022-05-30 | |||||||||||
Sponsor Name:Astex Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia | |||||||||||||
Medical condition: Acute Myeloid Leukemia (AML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003281-40 | Sponsor Protocol Number: ASTX727-03 | Start Date*: 2021-10-19 | ||||||||||||||||
Sponsor Name:Astex Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | ||||||||||||||||||
Medical condition: Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Restarted) BE (Ongoing) ES (Restarted) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003942-18 | Sponsor Protocol Number: ASTX727-06 | Start Date*: 2021-09-03 | ||||||||||||||||||||||||||
Sponsor Name:Astex Pharmaceuticals, Inc. | ||||||||||||||||||||||||||||
Full Title: An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | ||||||||||||||||||||||||||||
Medical condition: Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SK (Ongoing) BG (Ongoing) ES (Ongoing) LT (Ongoing) HU (Ongoing) AT (Ongoing) DE (Ongoing) IT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003395-12 | Sponsor Protocol Number: ASTX727-02 | Start Date*: 2019-11-14 | |||||||||||||||||||||
Sponsor Name:Astex Pharmaceuticals, Inc. | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Mye... | |||||||||||||||||||||||
Medical condition: Acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) AT (Completed) IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001076-34 | Sponsor Protocol Number: ABNL-MARRO-001 | Start Date*: 2023-06-12 | ||||||||||||||||
Sponsor Name:Theradex (Europe) Ltd. | ||||||||||||||||||
Full Title: The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes | ||||||||||||||||||
Medical condition: Myelodysplastic syndrome/Myeloproliferative Neoplasm Overlap Syndromes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003685-40 | Sponsor Protocol Number: GFM-DACORAL-DLI | Start Date*: 2020-12-28 | ||||||||||||||||
Sponsor Name:Groupe Francophone des Myélodysplasies (GFM) | ||||||||||||||||||
Full Title: A PHASE II PROSPECTIVE STUDY “GFM-DACORAL-DLI” ASTX727 AND DONOR LYMPHOCYTE INFUSIONS (DLI) AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO SCT) IN VERY HIGH RISK MDS OR AML PATIENTS | ||||||||||||||||||
Medical condition: Patients with high risk myelodysplastic syndrome or acute myeloid leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.